Compare Crispr Therapeutics AG (CRSP) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Warner Music Group Corp — how do they compare? Crispr Therapeutics AG trades at $53.89 (market cap $5.23B), while Warner Music Group Corp trades at $24.57 (market cap $13.12B). The key difference: Warner Music Group Corp is far larger — about 2.5× Crispr Therapeutics AG's market cap, and Warner Music Group Corp pays a 3.19% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WMG | |
|---|---|---|
Market Cap | $5.23B | $13.12B |
Sector | Health | Media |
52-Week High | $76.78 | $34.72 |
52-Week Low | $44.34 | $23.65 |
Enterprise Value | $3.65B | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Warner Music Group (WMG) trades at $24.62, down 6.78% in the past 24 hours, reflecting bearish technical momentum. The stock shows mixed fundamentals with recent earnings beats in Q1 and Q2 2026 but declining net income margins from 9.3% in 2022 to 5.44% in 2025. Strong institutional buying interest and a 66.66% analyst buy rating provide support despite near-term weakness.
WMG presents a compelling value opportunity with reasonable valuation multiples (P/E 20.06, P/S 1.8) and robust 9.2% projected 2026 net margin. Key risks include leadership transitions following the CFO's departure and streaming market competition, but strategic partnerships and price increases support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
